Paul A. Dickinson

4.1k total citations · 1 hit paper
42 papers, 3.1k citations indexed

About

Paul A. Dickinson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Paul A. Dickinson has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Paul A. Dickinson's work include Lung Cancer Treatments and Mutations (11 papers), Drug Solubulity and Delivery Systems (9 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Paul A. Dickinson is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Drug Solubulity and Delivery Systems (9 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Paul A. Dickinson collaborates with scholars based in United Kingdom, United States and Sweden. Paul A. Dickinson's co-authors include Mireille Cantarini, Paul Frewer, Kathryn H. Brown, Yuichiro Ohe, Malcolm Ranson, Pasi A. Jänne, David Planchard, Enriqueta Felip, James Chih‐Hsin Yang and Serban Ghiorghiu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Paul A. Dickinson

42 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Pasi A. Jänne, James Chih‐Hsin Yang et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul A. Dickinson United Kingdom	21	1.7k	1.5k	977	653	426	42	3.1k
Paul Statkevich United States	35	971 0.6×	2.1k 1.4×	1.6k 1.6×	89 0.1×	646 1.5×	92	4.8k
Stijn L.W. Koolen Netherlands	25	755 0.4×	1.1k 0.7×	545 0.6×	141 0.2×	253 0.6×	155	2.3k
Ana Ruiz-Garcı́a United States	23	806 0.5×	952 0.6×	622 0.6×	177 0.3×	159 0.4×	65	2.0k
Joseph Ciccolini France	36	683 0.4×	2.4k 1.6×	1.6k 1.7×	78 0.1×	677 1.6×	196	4.5k
Raymond J. Hohl United States	40	624 0.4×	1.5k 1.0×	2.3k 2.3×	73 0.1×	818 1.9×	138	4.9k
E. Brendel Germany	21	558 0.3×	818 0.5×	891 0.9×	146 0.2×	310 0.7×	53	2.1k
Jürgen Venitz United States	29	611 0.4×	607 0.4×	1.1k 1.1×	62 0.1×	424 1.0×	87	2.9k
Jan H. Beumer United States	40	683 0.4×	2.1k 1.4×	2.3k 2.4×	49 0.1×	489 1.1×	234	4.8k
Shinji Yamazaki United States	25	1.1k 0.6×	1.2k 0.8×	1.4k 1.4×	40 0.1×	326 0.8×	76	3.0k
Michel Vidal France	31	465 0.3×	897 0.6×	1.6k 1.6×	45 0.1×	249 0.6×	182	3.3k

Countries citing papers authored by Paul A. Dickinson

Since Specialization

Citations

This map shows the geographic impact of Paul A. Dickinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Dickinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Dickinson more than expected).

Fields of papers citing papers by Paul A. Dickinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Dickinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Dickinson. The network helps show where Paul A. Dickinson may publish in the future.

Co-authorship network of co-authors of Paul A. Dickinson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Dickinson. A scholar is included among the top collaborators of Paul A. Dickinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Dickinson. Paul A. Dickinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gajjar, Parmesh, et al.. (2022). Determining bioequivalence possibilities of long acting injectables through population PK modelling. European Journal of Pharmaceutical Sciences. 179. 106296–106296. 9 indexed citations

Matas, Marcel de, et al.. (2021). Exploring a model-based analysis of patient derived xenograft studies in oncology drug development. PeerJ. 9. e10681–e10681. 6 indexed citations

Selen, Arzu, Anette Müllertz, Filippos Kesisoglou, et al.. (2020). Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products. The AAPS Journal. 22(5). 97–97. 3 indexed citations

Harvey, R. Donald, Nicolás Isambert, Saeed Rafii, et al.. (2016). Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.. Journal of Clinical Oncology. 34(15_suppl). e14098–e14098. 5 indexed citations

Planchard, David, Kathryn H. Brown, Dong‐Wan Kim, et al.. (2016). Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology. 77(4). 767–776. 115 indexed citations

Dickinson, Paul A., Mireille Cantarini, Paul Frewer, et al.. (2016). Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition. 44(8). 1201–1212. 105 indexed citations

Jänne, Pasi A., James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 372(18). 1689–1699. 1585 indexed citations breakdown →

Kostewicz, Edmund, Bertil Abrahamsson, Marcus E. Brewster, et al.. (2013). In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences. 57. 342–366. 299 indexed citations

Larsen, Anne, Richard A. Barker, Andrew R. Phillips, et al.. (2012). Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation. European Journal of Pharmaceutical Sciences. 48(1-2). 339–350. 88 indexed citations

10.

Polli, James E., Jack Cook, Barbara M. Davit, et al.. (2012). Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence. The AAPS Journal. 14(3). 627–638. 15 indexed citations

11.

Thörn, Helena, Anna Lundahl, J. A. Schrickx, Paul A. Dickinson, & Hans Lennernäs. (2011). Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. European Journal of Pharmaceutical Sciences. 43(3). 89–98. 51 indexed citations

12.

Selen, Arzu, Anette Müllertz, Paul A. Dickinson, et al.. (2010). Meeting Report: Applied Biopharmaceutics and Quality by Design for Dissolution/Release Specification Setting: Product Quality for Patient Benefit. The AAPS Journal. 12(3). 465–472. 23 indexed citations

13.

Thörn, Helena, Mikael Hedeland, Ulf Bondesson, et al.. (2009). Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions. Drug Metabolism and Disposition. 37(11). 2186–2196. 15 indexed citations

14.

Dickinson, Paul A., et al.. (2008). Clinical Relevance of Dissolution Testing in Quality by Design. The AAPS Journal. 10(2). 380–390. 87 indexed citations

15.

Kellaway, I.W., et al.. (2007). An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. Journal of Controlled Release. 122(1). 79–85. 16 indexed citations

16.

Dickinson, Paul A., et al.. (2007). The effects of pharmaceutical excipients on drug disposition. Advanced Drug Delivery Reviews. 59(15). 1482–1503. 87 indexed citations

17.

Dickinson, Paul A. & Ashwin Nayak. (2006). Approximate Randomization of Quantum States With Fewer Bits of Key. AIP conference proceedings. 864. 18–36. 17 indexed citations

18.

Seville, Peter C., Claire Simons, Glyn Taylor, & Paul A. Dickinson. (2000). Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity. International Journal of Pharmaceutics. 195(1-2). 13–16. 3 indexed citations

19.

Kellaway, I.W., et al.. (1999). Improved Nasal Bioavailability of FITC-Dextran (M_w4300) from Mucoadhesive Microspheres in Rabbits. Journal of drug targeting. 7(5). 355–361. 23 indexed citations

20.

Dickinson, Paul A. & Glyn Taylor. (1996). Pulmonary first-pass and steady-state metabolism of phenols.. Pharmaceutical Research. 13(5). 744–748. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact